Baune BT
Department of Psychiatry, University of Münster, Münster, Germany; Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
ArticleKetamine
Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.
ArticleKetamine
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.
ArticleKetamine
Esketamine multi-omic biomarker evaluation in major depressive disorder (EMBER-MDD): concept, objectives and methodologies of a non-clinical investigator-initiated study.
Article5-MeO-DMT
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
ArticleKetamine
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
ArticleKetamine
Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.
ArticleKetamine
Effect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review.
ArticleKetamine
Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders.
ArticleKetamine
[Clinical management of treatment-resistant depression].
ArticleKetamine
Combination of Acute and Maintenance Esketamine Treatment With Adjunctive Long-Term Vagus Nerve Stimulation in Difficult-to-Treat Depression.
ArticleKetamine
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
ArticleKetamine